The SAMe-TT₂R₂ score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation

ABSTRACT

Oral anticoagulation therapy is essential in patients with atrial fibrillation and clinicians need guidance on decision-making between the vitamin K antagonists (VKA), e.g. warfarin, or non-vitamin K antagonist oral anticoagulants. Observational studies have shown that patients who receive VKA therapy spend a significant percentage of their time with international normalized ratio values outside of the therapeutic range (time in therapeutic range, TTR <60%.) Recently, a clinical score has been developed with commonly encountered clinical features, the SAMe-TT₂R₂ score, to help decision-making with regard to whether a patient is likely to do well, or not, with a VKA. Those with a SAMe-TT₂R₂ score of 0–1 are likely to do well on a VKA, while those with a SAMe-TT₂R₂ score ≥2 are on probability going to achieve suboptimal TTR. In this article, we provide an overview of the main published retrospective and prospective studies that have validated the SAMe-TT₂R₂ score and its value for decision-making in daily clinical practice.

KEYWORDS:

• SAMe-TT₂R₂
• vitamin K antagonists
• NOAC
• atrial fibrillation
• CHA₂DS₂-VASc